Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I, prospective, three-arm, open-label, randomized, first in human (FIH)
clinical trial to assess the safety and immunogenicity of EgyVax vaccine candidate for
prophylaxis of SARS-CoV-2 infection (COVID-19).
Phase:
Phase 1
Details
Lead Sponsor:
Eva Pharma
Collaborators:
Ministry of Higher Education and Scientific Research, Egypt The Supreme Council of University Hospitals, Egypt Veterinary Serum & Vaccine Research Institute (VSVRI), Egypt